About Briganix (Brigatinib)

BRIGANIX is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.

This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

How To Know Orginal Beacon Products ?

All Beacon products have a Unique QR Code for Authenticity.

After scanning The QR Code you will see Box information & System Information are Same.

Don't Purchase any product verify By Others.

To avoid Fake medicine,Please flow the Verification Guide


Briganix(Brigatinib): Each capsule contains 30 mg, 90 mg & 180 mg

ORDER NOW

DOSAGE AND ADMINISTRATION:

90 mg orally once daily for the first 7 days; if tolerated, increase to 180 mg orally once daily.May be taken with or without food.

WARNINGS AND PRECAUTIONS:

  • Administer BRIGANIX until disease progression or unacceptable toxicity

  • If BRIGANIX is interrupted for 14 days or longer for reasons other than adverse reactions, resume treatment at 90 mg once daily for 7 days before increasing to the previously tolerated dose

  • BRIGANIX tablets should be swallowed whole. Do not crush or chew tablets

  • If a dose of BRIGANIX is missed or vomiting occurs after taking a dose, do not administer an additional dose. Take next dose at the scheduled time

  • Avoid grapefruit or grapefruit juice as it may increase plasma concentrations of BRIGANIX

    • For more Please see the Package insert: Click

    GLOBAL PATIENT SUPPORT PROGRAM

    Life saving drugs are either beyond the reach of general people or not available in many countries. Because of the patent exemptions for Bangladeshi companies, Beacon Pharmaceuticals can manufacture the patented drugs to support the global patients.


    REGISTERED & LICENSED BY REGULATORY AUTHORITY OF BANGLADESH

    Briganix 90 : Marketing Authorization Number: 341-357-477

    Briganix 180 : Marketing Authorization Number: 341-358-010

     

     

    HEAD OFFICE

    9/B/2,Toyenbee Circular Road,
    Motijheel,Dhaka-1223, Bangladesh
    Phone: +880-2-57165371 / 79
    E-mail: info@beaconmedicare.com.bd
    Web:  www.beaconmedicare.com.bd

    MORE INFORMATION